What this study is
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.
What's being tested
- Study sample collection
Intervention · OTHER
Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.
Study details
- Official title
- Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy
- Sponsor
- University of Missouri-Columbia
- Conditions
- Hematological Malignancy
- Enrolling
- 50 people
- Starts
- 2020-03-20
- Est. completion
- 2027-03-20
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- All hematological malignancy patients.
- Must be 18 years old.
You can't join if
- Participants with impaired decision-making capacities;
- Pregnant women or fetuses;
- Children (under 18 in Missouri, also dependent on State law);
- Non-viable neonates or neonates of uncertain viability (neonates=newborns);
- Non-English-speaking subjects;
- Prisoners.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Missouri
Columbia, Missouri, United States
- Xunlei Kang, MD.PhD · Contact5738844524kangxu@health.missouri.edu
Recruiting
Study team
Sponsor
University of Missouri-Columbia
Study ID 2018932
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.